Apurv Agrawal, MD
Hematology & Oncology · Brick, NJNPI 1639188766
Payments from drug & device makers
Across 296 payments — averaging $2817.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$280K
- Incyte Corporation$194K
- Genentech, Inc.$154K
- Takeda Pharmaceuticals U.S.A., Inc.$50K
- Amgen$25K
- Acerta Pharma LLC$25K
- plus $106K from 34 others
Across 6 payments — averaging $504.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Eli Lilly$16
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 12 | $279,824 |
| Incyte Corporation | 110 | $194,470 |
| Genentech, Inc. | 62 | $154,051 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $50,339 |
| Amgen | 9 | $24,871 |
| Acerta Pharma LLC | 5 | $24,632 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $20,266 |
| Beigene, Ltd. | 11 | $19,726 |
| Novocure Inc. | 4 | $19,000 |
| Helsinn Healthcare SA | 3 | $13,900 |
| Macrogenics, Inc. | 1 | $8,176 |
| CTI Biopharma Corp. | 6 | $6,340 |
| Johnson & Johnson | 7 | $5,520 |
| Halozyme Inc | 1 | $3,513 |
| AstraZeneca | 4 | $3,372 |
| Bristol Myers Squibb | 3 | $3,087 |
| Astrazeneca UK Limited | 1 | $1,348 |
| Morphosys, US Inc. | 1 | $485 |
| ASD Specialty Healthcare, LLC | 1 | $218 |
| EMD Serono, Inc. | 3 | $190 |
| Seagen Inc. | 2 | $126 |
| E.r. Squibb & Sons, L.L.C. | 6 | $124 |
| Boston Scientific | 1 | $83 |
| Novartis | 4 | $75 |
| Genentech USA, Inc. | 3 | $40 |
| Springworks Therapeutics, Inc. | 2 | $37 |
| Merck | 2 | $34 |
| Pharmacosmos Therapeutics Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Sanofi | 2 | $26 |
| Gilead(2 entities) | 2 | $26 |
| Exelixis Inc. | 1 | $22 |
| Foundation Medicine, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Spectrum Pharmaceuticals Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Myovant Sciences Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
How this compares
$834,101 in reported general payments places this provider in the 90th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Brick
- Bruno FangEast Brunswick$8.5M
- Charles FarberMorristown$4.6M
- Rajat BannerjiNew Brunswick$3.3M
- Eleonora TeplinskyParamus$2.6M
- Mohamad CherryMorristown$1.9M
- Evan NaylorManahawkin$1.3M
- James OrsiniBelleville$1.3M
- Eli KirshnerWestwood$1.2M
- Linda DanieuLivingston$1.2M
- Steven PapishMorristown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.